Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.

Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Dec;31(12):1807-1815. doi: 10.1038/s41379-018-0086-7. Epub 2018 Jun 28.

PMID:
29955142
2.

p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.

de Roos MA, de Bock GH, de Vries J, van der Vegt B, Wesseling J.

J Surg Res. 2007 Jun 1;140(1):109-14. Epub 2007 Feb 7.

PMID:
17291532
3.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

PMID:
30429518
4.

Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study.

Castellano I, Marchiò C, Tomatis M, Ponti A, Casella D, Bianchi S, Vezzosi V, Arisio R, Pietribiasi F, Frigerio A, Mano MP, Ricardi U, Allia E, Accortanzo V, Durando A, Bussolati G, Tot T, Sapino A.

Mod Pathol. 2010 Feb;23(2):260-9. doi: 10.1038/modpathol.2009.169. Epub 2009 Nov 13.

5.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

PMID:
30410060
6.

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID:
7496840
7.

Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.

Aguiar FN, Mendes HN, Cirqueira CS, Bacchi CE, Carvalho FM.

Clinics (Sao Paulo). 2013 May;68(5):638-43. doi: 10.6061/clinics/2013(05)010.

8.

Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.

Cai Z, Zhang C, Zou Y, Lu C, Hu H, Qian J, Jiang L, Hu G.

Int J Clin Oncol. 2017 Aug;22(4):660-666. doi: 10.1007/s10147-017-1103-4. Epub 2017 Feb 27.

PMID:
28243945
9.

Predictors of disease progression in ductal carcinoma in situ of the breast and vascular patterns.

Adler EH, Sunkara JL, Patchefsky AS, Koss LG, Oktay MH.

Hum Pathol. 2012 Apr;43(4):550-6. doi: 10.1016/j.humpath.2011.06.004. Epub 2011 Sep 16.

PMID:
21925705
10.
11.

Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ.

Roguljic A, Spagnoli G, Juretic A, Sarcevic B, Banovic M, Beketic Oreskovic L.

Oncol Lett. 2018 Dec;16(6):7245-7255. doi: 10.3892/ol.2018.9544. Epub 2018 Oct 3.

12.

Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.

13.
14.

Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.

Fadare O, Dadmanesh F, Alvarado-Cabrero I, Snyder R, Stephen Mitchell J, Tot T, Wang SA, Ghofrani M, Eusebi V, Martel M, Tavassoli FA.

Am J Surg Pathol. 2006 Nov;30(11):1445-53.

PMID:
17063087
15.

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

PMID:
7914825
16.

Microinvasive Carcinoma versus Ductal Carcinoma In Situ: A Comparison of Clinicopathological Features and Clinical Outcomes.

Kim M, Kim HJ, Chung YR, Kang E, Kim EK, Kim SH, Kim YJ, Kim JH, Kim IA, Park SY.

J Breast Cancer. 2018 Jun;21(2):197-205. doi: 10.4048/jbc.2018.21.2.197. Epub 2018 Jun 20.

17.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0286-9. [Epub ahead of print]

PMID:
31175327
18.

Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence.

Lim JY, Yoon SO, Hong SW, Kim JW, Choi SH, Cho JY.

World J Gastroenterol. 2012 Oct 21;18(39):5581-8. doi: 10.3748/wjg.v18.i39.5581.

19.

The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas.

Jang SM, Han H, Jang KS, Jun YJ, Jang SH, Min KW, Chung MS, Paik SS.

J Breast Cancer. 2012 Jun;15(2):172-80. doi: 10.4048/jbc.2012.15.2.172. Epub 2012 Jun 28.

20.

Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.

Merkin RD, Vanner EA, Romeiser JL, Shroyer ALW, Escobar-Hoyos LF, Li J, Powers RS, Burke S, Shroyer KR.

Hum Pathol. 2017 Apr;62:23-32. doi: 10.1016/j.humpath.2016.10.006. Epub 2016 Nov 2.

PMID:
27816721

Supplemental Content

Support Center